Orchid Pharma Limited announces NCLT approval for merger with Dhanuka Laboratories
Orchid Pharma · Pharmaceuticals & Biotechnology
Key highlights
- NCLT Chennai approved the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited on June 5, 2026
- The Appointed Date for the merger is April 1, 2024, and the Scheme will be effective upon completion of specified procedural steps
- A certified copy of the NCLT order was published on June 11, 2026, and the company will update exchanges upon Scheme effectiveness
Why it's rated notable: The NCLT sanctioned the amalgamation of Dhanuka Laboratories into Orchid Pharma, which is binding, but the filing states no value involved, so the level stays at medium rather than being sized against the ₹5,194 crore market value.
Original filing
Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited And Orchid Pharma Limited
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Orchid Pharma
- Fundraise / allotmentOrchid Pharma Limited QIP proceeds utilization and monitoring report for Q2 FY 2026-27
- Fundraise / allotmentNotableOrchid Pharma Ltd QIP monitoring report for quarter ended June 30, 2026
- Fundraise / allotmentNotableOrchid Pharma allots 4,45,86,052 shares to Dhanuka Laboratories holders in amalgamation
- Acquisition / mergerNotableOrchid Pharma announces effective date of Scheme of Amalgamation with Dhanuka Laboratories
- Acquisition / mergerNotableOrchid Pharma Limited announces NCLT approval for amalgamation with Dhanuka Laboratories
Other acquisition / merger filings this fortnight
- Acquisition / mergerGSP Crop ScienceGSP Crop Science Limited Q2 FY2027 financial results and corporate updates disclosed
- Acquisition / mergerGSP Crop ScienceGSP Crop Science Limited reports Q2 2026 financials and management changes
- Acquisition / mergerLinde IndiaLinde India acquires 100% stake in Airtech Cryogenic Gases Pvt Ltd for ₹111.20 crore
- Acquisition / mergerManipal Health EnterprisesManipal Health Enterprises completes acquisition of Kinder Women’s Hospital
- Acquisition / mergerPramodini MedicarePramodini Medicare Ltd reports H1 FY2027 financials and IPO funds utilization
- Acquisition / mergerPramodini MedicarePramodini Medicare Ltd reports Q2 FY27 financials and IPO fund utilization
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.